Cox_cmyk_300dpi (2)Pipelines across the industry are exploding with potential biologic therapies, many of which could treat large patient populations. How can our industry make sure these potential therapies come to fruition and reach their intended patients?

A critical step involves implementing disruptive manufacturing technologies, processes and capabilities. This will maximize the output of large-scale manufacturing plants and help deliver the pipelines. One key player in this innovative technique is Biogen Idec., a company that develops therapies for people living with serious neurological, autoimmune and hematologic disorders.

Would you like to hear directly from Biogen about the details of this growing state-of-the-art technology?

You have the opportunity to gain in-depth knowledge about biopharmaceutical pipelines from Biogen’s Executive Vice President of Pharmaceutical Operations and Technology: John Cox. Mr. Cox oversees Biogen’s production facilities, supply chain operations, technical development, quality and engineering around the globe. He has led the operations of two world-class biopharmaceutical manufacturing facilities, and has overseen small-scale cell culture and purification laboratories. Mr. Cox brings more than 20 years of experience in biopharmaceuticals with roles of increasing responsibility at Biogen.

At ISPE Annual Meeting, Mr. Cox will give a comprehensive keynote presentation about success in biologic therapies through innovations in protein development and manufacturing.

To take advantage of this exclusive learning opportunity, register soon – the early bird deadline ends October 11!

RELATED POSTS